Bonavuth Pek

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 311 citations

Pharmacy, Pharmacology, Pharmacotherapy +6

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

Andrew Menzies‐Gow, Michael E. Wechsler, Christopher E. Brightling et al. · The Lancet Respiratory Medicine · 2023 · 141 citations · Full text

Life Sciences, Immunology, Internal Medicine +13

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial

Gary T. Ferguson, J. Mark FitzGerald, Eugene R. Bleecker et al. · The Lancet Respiratory Medicine · 2017 · 123 citations

Pharmacy, Pharmacology, Pharmacotherapy +7

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

Aili L. Lazaar, Bruce E. Miller, Alison Donald et al. · Respiratory Research · 2020 · 71 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial

Dave Singh, Christopher E. Brightling, Klaus F. Rabe et al. · The Lancet Respiratory Medicine · 2024 · 64 citations · Full text

Medicine, Internal Medicine, Pharmacology +10